Oramed Pharmaceuticals (ORMP) Cash from Investing Activities (2010 - 2026)

Oramed Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$19.5 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 182.52% year-over-year to -$19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$37.7 million (down 137.87% YoY) and the FY2025 annual result came in at $5.4 million, down 94.86% from the prior year.
• Cash from Investing Activities was -$19.5 million for Q1 2026 at Oramed Pharmaceuticals, down from -$1.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $94.7 million in Q2 2024 and bottomed at -$75.1 million in Q3 2023.
• A 5-year average of $2.9 million and a median of $7.4 million in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 6212.45% — and 2024, when it soared 743.47%.
• Oramed Pharmaceuticals' Cash from Investing Activities stood at $11.3 million in 2022, then surged by 166.4% to $30.0 million in 2023, then tumbled by 48.58% to $15.4 million in 2024, then sank by 110.92% to -$1.7 million in 2025, then tumbled by 1057.24% to -$19.5 million in 2026.
• Business Quant data shows ORMP's Cash from Investing Activities at -$19.5 million in Q1 2026, -$1.7 million in Q4 2025, and $38.4 million in Q3 2025.